Xin Jing Bao·2025-07-01 01:37Core Viewpoint - The approval of Ma Shidu Peptide as the world's first GCG/GLP-1 dual receptor agonist for weight management marks a significant development in the obesity treatment market, potentially disrupting the current dominance of existing products like Semaglutide [1][2][4]. Group 1: Product Approval and Market Impact - Ma Shidu Peptide, developed by Innovent Biologics in collaboration with Eli Lilly, has been approved for long-term weight control in adults with obesity or overweight [2]. - The drug is expected to break the current duopoly in the GLP-1 market, which has been largely dominated by Semaglutide and Tirzepatide [1][4]. - The global market for GLP-1 drugs is projected to exceed $50 billion in 2024, with Semaglutide contributing approximately $25 billion [7]. Group 2: Clinical Research and Efficacy - The approval was based on the results of the Phase III clinical trial (GLORY-1), which demonstrated significant weight loss in participants, with a mean percentage change from baseline of -12.0% and -14.8% for the 4mg and 6mg doses, respectively [3]. - The trial also showed that Ma Shidu Peptide significantly reduced liver fat content and improved various cardiometabolic indicators [3]. Group 3: Competitive Landscape - The GLP-1 receptor agonist market is becoming increasingly competitive, with over ten domestic companies in China actively developing similar drugs [4][11]. - Semaglutide's sales reached approximately $8.4 billion in the first quarter of 2023, surpassing Merck's Keytruda, which generated $7.205 billion [5]. - Tirzepatide, a competitor, has also shown promising results in head-to-head studies against Semaglutide, indicating a rapidly evolving competitive environment [6]. Group 4: Future Prospects and Trends - The market for GLP-1 weight management drugs in China is expected to grow significantly, with projections indicating a market size exceeding 15 billion yuan by 2025 [7]. - The trend is shifting from single-target to multi-target GLP-1 drugs, with several new candidates showing potential in clinical trials [8][9]. - Domestic companies are increasingly pursuing overseas licensing agreements for their GLP-1 drugs, indicating a strategic move to expand their market presence [10].